• Fosinopril Sodium: Precision ACE Inhibitor for Hypertension

  2026-07-17

  Fosinopril sodium is a third-generation ACE inhibitor with dual renal-hepatic elimination and robust blood pressure-lowering efficacy. Its unique phosphinic acid moiety enables strong zinc ion binding, supporting reliable cardiovascular and renal model applications. APExBIO’s Fosinopril sodium offers reproducible performance for translational hypertension research.

• Strategic Use of 5-(N,N-dimethyl)-Amiloride Hydrochloride in

  2026-07-16

  This article provides translational researchers with actionable insights into leveraging 5-(N,N-dimethyl)-Amiloride (hydrochloride) for dissecting Na+/H+ exchanger mechanisms in vascular and cardiac models. We synthesize biomarker breakthroughs—especially moesin’s diagnostic role in sepsis—with advanced guidance on experimental design and translational impact. By differentiating from standard product summaries, this discussion integrates competitive tool analysis, protocol recommendations, and a forward-looking outlook, establishing APExBIO’s DMA as a cornerstone for next-generation cardiovascular and endothelial injury research.

• Fosinopril Sodium: Clinical Pharmacokinetics and Research Im

  2026-07-16

  This review details the unique dual excretion and pharmacodynamic profile of Fosinopril sodium as presented in a landmark clinical pharmacokinetics study. The findings clarify its distinct advantages for hypertension and cardiovascular research, particularly in models involving renal impairment, and outline best practices for translational application.

• Azilsartan (TAK-536): Unveiling AT1 Inhibition Beyond Cardio

  2026-07-15

  Explore how Azilsartan (TAK-536) advances research beyond cardiovascular applications, targeting the renin-angiotensin system in neuroinflammatory and astrocyte–microglia models. Discover unique mechanistic insights and protocol guidance grounded in recent scientific breakthroughs.

• Chemoproteomic Mapping Reveals CDK4 Control of 4E-BP1 in Can

  2026-07-15

  Mitchell et al. introduced a chemoproteomic crosslinking assay to identify kinase-substrate relationships with site specificity, revealing that CDK4 directly phosphorylates the translation suppressor 4E-BP1. This discovery clarifies mechanisms of mTORC1 inhibitor resistance in cancer and enables new strategies for dissecting cap-dependent translation regulation.

• Regorafenib (BAY 73-4506): Multikinase Inhibitor for Angioge

  2026-07-14

  Regorafenib (BAY 73-4506) is a potent multikinase inhibitor that disrupts angiogenic and oncogenic signaling in cancer models. It displays nanomolar IC50 values against VEGFRs, PDGFRβ, KIT, RET, and RAF kinases, with robust evidence for efficacy in tumor growth inhibition and metastasis suppression. APExBIO supplies Regorafenib (SKU A8236) as a research-grade compound for advanced cancer biology and angiogenesis research.

• Pesticide Spray Drift: UAV vs. Knapsack Sprayer Using Rhodam

  2026-07-14

  This study provides the first direct field comparison of pesticide spray drift from UAV and traditional electric knapsack sprayer (EKS) applications, using Rhodamine B as a quantitative fluorescent tracer. The findings reveal UAVs produce substantially greater drift distances and higher off-target deposition, offering essential baseline data for environmental risk assessment and regulatory frameworks.

• Applied Use of (-)-Blebbistatin in Cytoskeletal Dynamics Res

  2026-07-13

  (-)-Blebbistatin, a selective non-muscle myosin II inhibitor from APExBIO, empowers researchers to dissect actin-myosin interactions with precision. This guide delivers practical workflows, troubleshooting strategies, and experimental insights for maximizing reproducibility in cell mechanics and cardiac research applications.

• Gastrodin Regulates RAS–SIRT3 and Astrocyte Phenotypes via M

  2026-07-13

  This study demonstrates that gastrodin modulates the renin-angiotensin system (RAS)–SIRT3 axis and astrocyte inflammatory phenotype through microglia-mediated signaling. Importantly, it reveals that AT1 receptor inhibition, including with Azilsartan, alters the expression of phenotype markers in reactive astrocytes, providing mechanistic insight into neuroinflammation control.

• Resiquimod (R-848): Advanced Immune Modulation in Cancer Res

  2026-07-12

  Explore how Resiquimod (R-848) enables next-generation innate immune response modulation and enhances cancer immunotherapy research. This article reveals unique mechanistic insights and translational applications beyond standard immunological tools.

• Angiotensin II in AAA Models: Mechanistic Insights and Proto

  2026-07-10

  Discover how Angiotensin II advances abdominal aortic aneurysm (AAA) research through precise mechanistic modeling. This in-depth article unpacks the peptide’s role in vascular remodeling and offers expert guidance on optimizing Angiotensin II assays.

• EPI-001: Transforming Androgen Receptor Inhibition in CRPC R

  2026-07-09

  Explore how EPI-001, a potent androgen receptor N-terminal domain inhibitor, is revolutionizing prostate cancer and TNBC research. This article delivers new insights into mechanism, assay design, and translational impact, setting it apart from existing resources.

• ISRIB (trans-isomer): PERK Inhibitor for Fibrosis and ER Str

  2026-07-09

  ISRIB (trans-isomer) delivers selective, robust inhibition of the integrated stress response, enabling advanced ER stress, fibrosis, and cognitive enhancement research. Leveraging new insights into ATF4-driven enhancer programs, this PERK inhibitor offers unmatched precision in both in vitro and in vivo workflows.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-07-08

  This study uncovers that naturally occurring angiotensin peptides, particularly Angiotensin II and its N-terminal truncated forms, significantly increase the binding of the SARS-CoV-2 spike protein to AXL, an alternative viral entry receptor. These findings highlight a novel molecular intersection between the renin–angiotensin system and COVID-19 pathogenesis, suggesting new avenues for therapeutic research.

• IL-1β/NF-κB-Mediated ACE2 Upregulation Drives Macrophage Inf

  2026-07-08

  Lee et al. identify a key mechanism by which IL-1β-driven NF-κB signaling induces ACE2 expression in macrophages, enabling their productive infection by SARS-CoV-2. The study introduces a humanized ACE2 mouse model, offering mechanistic insight into inflammatory regulation of viral susceptibility and highlighting implications for COVID-19 pathogenesis.

450 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page